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Abstract
BACKGROUND—It has been demonstrated that the humanized clivatuzumab tetraxetan 
(hPAM4) antibody targets pancreatic ductal carcinoma selectively. After a trial of 
radioimmunotherapy that determined the maximum tolerated dose of single-dose yttrium-90-
labeled hPAM4 (90Y-hPAM4) and produced objective responses in patients with advanced 
pancreatic ductal carcinoma, the authors studied fractionated radioimmunotherapy combined with 
low-dose gemcitabine in this disease.
METHODS—Thirty-eight previously untreated patients (33 patients with stage IV disease and 5 
patients with stage III disease) received gemcitabine 200 mg/m2 weekly for 4 weeks with 90Y-
hPAM4 given weekly in Weeks 2, 3, and 4 (cycle 1), and the same cycle was repeated in 13 
patients (cycles 2–4). In the first part of the study, 19 patients received escalating weekly 90Y 
doses of 6.5 mCi/m2, 9.0 mCi/m2, 12.0 mCi/m2, and 15.0 mCi/m2. In the second portion, 19 
additional patients received weekly doses of 9.0 mCi/m2 or 12.0 mCi/m2.
RESULTS—Grade 3/4 thrombocytopenia or neutropenia (according to version 3.0 of the 
National Cancer Institute’s Common Terminology Criteria for Adverse Events) developed in 28 of 
38 patients after cycle 1 and in all retreated patients; no grade >3 nonhematologic toxicities 
occurred. Fractionated dosing of cycle 1 allowed almost twice the radiation dose compared with 
single-dose radioimmunotherapy. The maximum tolerated dose of 90Y-hPAM4 was 12.0 mCi/m2 
weekly for 3 weeks for cycle 1, with ≤9.0 mCi/m2 weekly for 3 weeks for subsequent cycles, and 
that dose will be used in future trials. Six patients (16%) had partial responses according to 
computed tomography-based Response Evaluation Criteria in Solid Tumors, and 16 patients 
(42%) had stabilization as their best response (58% disease control). The median overall survival 
was 7.7 months for all 38 patients, including 11.8 months for those who received repeated cycles 
(46% [6 of 13 patients] ≥1 year), with improved efficacy at the higher radioimmunotherapy doses.
CONCLUSIONS—Fractionated radioimmunotherapy with 90Y-hPAM4 and low-dose 
gemcitabine demonstrated promising therapeutic activity and manageable myelosuppression in 
patients with advanced pancreatic ductal carcinoma.
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INTRODUCTION
Despite considerable efforts to improve the management of pancreatic ductal cancer (PDC), 
the only approved treatments for advanced disease offer minimal survival benefit (median 
survival, approximately 6 months).1–3 Recently, two multi-drug combinations reportedly 
improved survival but with substantial toxicities.4,5 In preclinical models, pancreatic cancer 
has been responsive to radioimmunotherapy (RAIT) with radiolabeled clivatuzumab 
tetraxetan (PAM4),6,7 a monoclonal antibody that specifically targets a mucin antigen that is 
produced in >85% of pancreatic adenocarcinomas and is absent in normal pancreas.8–10 
Hence, the PAM4 antibody was humanized (hPAM4), and a chelate conjugate was labeled 
with yttrium-90 (90Y-hPAM4), a therapeutic β-emitting radionuclide with an effective mean 
radiation path length of approximately 5 mm that is suitable for bulky tumors.
On the basis of clinical experience with external radiotherapy and other studies using 90Y-
labeled antibodies,11 we speculated that fractionated doses could deliver more radiation than 
a single bolus. Preclinical studies also indicated enhanced antitumor activity when 90Y-
hPAM4 was combined with gemcitabine,12–14 a known radiosensitizer.15 Clinically, low 
doses of gemcitabine with external radiotherapy were tolerated.16 In the first phase 1 trial of 
single-dose hPAM4 RAIT, the maximum tolerated dose (MTD) was identified as 20 
mCi/m2 (740 megabecquerels [MBq]/m2), with expected dose-limiting myelotoxicity.17 
Despite receiving only a single administration, several patients had an objective response. 
Hence, in the current study, we examined fractionated RAIT using 90Y-hPAM4 combined 
with low-dose gemcitabine in patients with advanced PDC. The overall objective of the 
study was to determine the MTD of this combination as first-line therapy. With escalating 
RAIT doses and a constant gemcitabine dose, patients optionally received repeated cycles. 
Correlative 18F-deoxyglucose–positron emission tomography (FDG-PET) and CA19-9 




The primary objectives were to evaluate the feasibility, safety, tolerability, and MTD of 
fractionated 90Y-hPAM4 in combination with low-dose gemcitabine (200 mg/m2) in a single 
cycle or in optional repeated cycles. Secondary objectives included assessment of tumor 
targeting, biodistribution, organ dosimetry, pharmacokinetics, immunogenicity, and efficacy 
(as determined according to Response Evaluation Criteria in Solid Tumors [RECIST], 
changes in CA19-9 serum titers, and survival).
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Previously untreated adults with histologically or cytologically confirmed stage III PDC 
(locally advanced, unresectable; N = 5) or stage IV PDC (metastatic; N = 33) had to have a 
Karnofsky performance status ≥70 and adequate hematologic parameters (eg, hemoglobin 
≥11 g/dL, absolute neutrophil count ≥2.0 × 109/L, platelets ≥150 × 109/L). Additional 
eligibility requirements included life expectancy >3 months, no known history of active 
cardiac or pulmonary disease, no major surgery within 4 weeks, and adequate renal and 
hepatic function at study entry (creatinine and bilirubin levels ≤1.5 times the institutional 
upper limit of normal and aspartate and alanine aminotransferase levels ≤2.0 times the 
institutional upper limit of normal). Patients were excluded if they had disease that was 
metastatic to the central nervous system; a single tumor mass that measured >10 cm in 
greatest dimension; grade >2 anorexia, nausea, vomiting, or signs of intestinal obstruction; 
known human immunodeficiency virus or hepatitis B or C positivity; or other concurrent 
medical or psychiatric conditions that could confound study interpretation or prevent the 
completion of study procedures.
The institutional review board at each participating site approved the study, and written 
informed consent was obtained from all patients. This study is registered as National 
Clinical Trial NCT00603863.
Treatment—Each treatment cycle was 4 weeks (Fig. 1). A 10-mg kit of 1,4,7,10-tetra-
azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA)-conjugated hPAM4 was labeled at 
local radiopharmacies.17,18 Patients received indium-111-labeled hPAM4 (111In-hPAM4) 
(3–5 mCi, 111–185 MBq) the first week to assess pharmacokinetics, antibody 
biodistribution, and radiation dosimetry estimates for 90Y-hPAM4, which was administered 
intravenously over 10 minutes without premedication once weekly for the next 3 weeks. 
Patients received gemcitabine (200 mg/m2 intravenously over 30 minutes) once weekly for 4 
weeks at least 2 days after the radioimmunoconjugate to permit adequate antibody 
accumulation at tumor sites before initiating radiosensitization based on prior studies.12–14
Dose-limiting toxicity (DLT) was defined for each treatment cycle as grade 4 hematologic 
toxicity that lasted ≥7 days or failure to recover to grade 1 within 12 weeks of completing a 
cycle, allowing supportive measures to aid recovery. Grade 4 nonhematologic toxicity of 
any duration and grade 3 toxicity that lasted ≥5 days also were considered DLTs. 
Transfusions and growth factors were permitted. At the discretion of the investigator, 
patients who completed a treatment cycle without DLT or overt progression of disease were 
eligible to receive additional treatment cycles at the same dose level after their hematologic 
toxicity recovered to grade 1 (typically 4–8 weeks later), which was at the discretion of the 
investigator.
A standard 3 + 3 dose escalation design was used to determine the MTD of the 90Y dosing 
for the initial treatment cycle, exploring dose levels of 6.5 mCi/m2 (241 MBq/m2), 9.0 
mCi/m2 (333 MBq/m2), 12.0 mCi/m2 (481 MBq/m2), and 15.0 mCi/m2 (555 MBq/m2) 
weekly for 3 weeks in the first part of the trial. In the second part, additional patients were 
enrolled to gain further experience at the 90Y MTD of the first cycle (12 mCi/m2 weekly for 
3 weeks) and at the next lower level (9.0 mCi/m2 weekly for 3 weeks).
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Study Assessments—Pharmacokinetics, imaging and dosimetry procedures have been 
reported.19–21 Evidence of tumor targeting was not required. To proceed with treatment, 
dose estimates for each cycle were required to be <300 centigrays (cGy) for red bone 
marrow, <3000 cGy for liver, and <2000 cGy for kidney and lung.20,21 Anti-hPAM4 
antibody response (HAHA) was assessed by using an enzyme-linked immunosorbent assay 
at baseline and at monthly intervals.17
Adverse events were classified according to the Medical Dictionary for Regulatory Affairs 
(MedDRA Maintenance and Support Services Organization, Northrop Grumman 
Information Systems, Chantilly, Va) and were graded according to version 3.0 of the 
National Cancer Institute’s Common Terminology Criteria for Adverse Events. Serum 
chemistry levels, physical examinations, vital signs, and urine analyses were performed over 
12 weeks after treatment, and weekly or more frequent blood counts were obtained for grade 
≥2 cytopenias. Serum levels of CA19-9 were obtained at baseline and then at 4 weeks, 8 
weeks, and 12 weeks after treatment. Computed tomography (CT) scans were evaluated by 
local radiologists at baseline and then until progression or at 4 weeks, 8 weeks, and 12 
weeks after RAIT, and the best treatment response at any of these evaluations was classified 
according to RECIST as a complete response (CR), a partial response (PR), stable disease 
(SD), or progressive disease (PD).22 18F-FDG-PET or PET/CT imaging was optional.
Statistical Analyses—Response rates were summarized using descriptive statistics. 
Overall survival (OS) was calculated from the first 90Y-hPAM4 dose to death or last 
contact. The duration of response was determined from the onset to the earliest occurrence 
of progression, death, or last contact. The probability of survival was estimated using the 
Kaplan-Meier method.
RESULTS
Forty-two adult patients with untreated stage III or IV PDC were enrolled. All had CT-
measurable disease, primarily involving the pancreas and/or liver, and most had elevated 
baseline CA19-9 serum levels (Table 1).
Treatment
Sixteen patients were treated during the first part of the trial and received their initial 
treatment cycle of 90Y-hPAM4 weekly for 3 weeks at doses of 6.5 mCi/m2 (N = 4), 9.0 
mCi/m2 (N = 4), 12.0 mCi/m2 (N = 3), and 15.0 mCi/m2 (N = 5). There were no DLTs 
except for 1 patient at the 15.0 mCi/m2 dose level who had grade 4 platelets that lasted >7 
days. However, further enrollment at the 15.0 mCi/m2 dose level was not pursued, because 2 
patients who initially were assigned to this level had required a dose reduction to meet the 
protocol-defined radiation dose restrictions to red bone marrow. Thus, after enrolling 3 more 
patients at the 12.0 mCi/m2 dose level without DLT and without having to reduce the dose 
because of dosimetry concerns, the MTD for the initial treatment cycle effectively was 
declared as 12.0 mCi/m2 weekly for 3 weeks. Nineteen additional patients were then treated 
during the second part of the study, including 11 patients at the MTD of 12.0 mCi/m2 
weekly for 3 weeks and 8 patients at the next lower level (9.0 mCi/m2 weekly for 3 weeks), 
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the latter patients being added because of concern that treatment at the single-cycle MTD 
level would compromise repeated cycles at the same dose level.
In total, 38 patients were treated, including 14 who had overt PD on CT scans at their first 
post-treatment evaluation and were ineligible for additional cycles. Although retreatment of 
the other 24 patients was at the investigator’s discretion, 11 patients were either removed 
from the study either to hospice or to pursue other treatment options. Thus, 25 patients 
received only 1 cycle, whereas 13 received 1 to 3 more treatment cycles, all at the same 90Y 
dose level as their first cycle (Table 2).
Adverse Events
Treatment was well tolerated, and no infusion reactions were reported. Thus, as expected, 
the main toxicity was hematologic, and there were dose-limiting cytopenias, which are 
detailed below. No abnormal patterns of changes occurred in standard serum chemistries, 
and no grade 3/4 adverse events were reported except for several isolated elevations of 
transaminases, alkaline phosphatase, or bilirubin, consistent with hepatic involvement, 
biliary obstruction, and other abdominal disease complications (data not shown). Most of the 
adverse events reported reflected gastrointestinal or hepatobiliary complications, pain or 
constitutional complaints expected in this population with advanced PDC, or cytopenias 
expected from treatment with RAIT and gemcitabine. Fifteen patients had 17 serious 
adverse events, including biliary or gastrointestinal obstruction (N = 5); febrile neutropenia 
(N = 3); and anemia, pneumonia, pretreatment cerebrovascular events, splenic abscess, 
mental status change, pleural effusion, ascites, hyponatremia, and prolonged 
thrombocytopenia complicated by rectal bleeding attributed to gastrointestinal tumor 
invasion (N = 1 each). Thirteen patients had 19 infections, which were treated with either 
intravenous antibiotics (febrile neutropenia, N = 3; pneumonia, ascending cholangitis, 
splenic abscess, urinary tract infection, N = 1 each) or orally (thrush, N = 4; urinary tract 
infection, N = 3; superficial lesions, N = 2; shingles, upper respiratory infection, 
Helicobacter pylori, N = 1 each). No therapy-related major bleeding or other significant 
adverse events occurred.
Myelosuppression and Dose-Limiting Toxicity
For the 38 treated patients, grade 4 anemia occurred only at the highest dose level, and grade 
3 anemia was infrequent. However, grade 3/4 neutropenia or thrombocytopenia developed in 
20 of 38 patients (53%) after cycle 1 and developed in all retreated patients. For patients 
with grade 3/4 events, the median time from the first dose of 90Y-hPAM4 to their nadir was 
3.8 weeks for platelets and 4.2 weeks for neutrophils during the first cycle, with similar 
times to nadirs after subsequent cycles (data not shown). For cycle 1, the incidence of grade 
3/4 neutropenia or thrombocytopenia among the 38 treated patients increased with dose 
levels, but there were only 3 DLTs (1 each at the 3 higher dose levels, all grade 4 
thrombocytopenia that lasted 1–2 weeks), and all cytopenias recovered from grade 3/4 
nadirs to grade 1 within a median of 1.9 weeks (maximum, 5.4 weeks) for platelets and 1.4 
weeks (maximum, 4.1 weeks) for neutrophils. In the second cycle, 3 of 4 patients who were 
retreated at dose levels ≤9.0 mCi/m2 weekly for 3 weeks had grade 3/4 cytopenias, but only 
1 patient at the 9.0 mCi/m2 weekly for 3 weeks dose level had a DLT (grade 4 
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thrombocytopenia for 10 days that was still grade 3 at 12 weeks). However, all 9 patients 
who were retreated at dose levels ≥12.0 mCi/m2 weekly for 3 weeks had grade 3/4 
cytopenias in the second cycle, often requiring transfusions, including 6 patients with DLTs 
(5 patients had thrombocytopenia that lasted >7 days, including 4 who still had grade 3/4 
thrombocytopenia at 12 weeks). Finally, 2 patients at 6.5 mCi/m2 weekly for 3 weeks 
encountered grade 3/4 cytopenias after receiving 3 or 4 cycles, including 1 DLT because of 
prolonged grade 4 thrombocytopenia. After completing this study, 20 patients received 
chemotherapy, predominantly gemcitabine alone or in combination with 1 or more other 
drugs (capecitabine, fluorouracil, oxaliplatin, docetaxel, and erlotinib), indicating that the 
myelosuppression from RAIT was reversible and did not affect patients’ ability to receive 
other forms of therapy after participating in this study.
Pharmacokinetics, Biodistribution, and Tumor Targeting
The mean ± standard deviation decay-corrected serum half-life of 111In-hPAM4 was 3.8 ± 
0.7 days (range, 1.7–4.8 days) for all 38 patients in the first cycle and 3.7 ± 0.9 days (range, 
2.4–5.4 days) for 13 retreated patients in the second cycle. 111In-hPAM4 imaging at each 
cycle revealed a normal antibody biodistribution pattern and no obvious changes with 
retreatment except for 2 patients who had rapid antibody blood clearance to the liver, which 
made them ineligible for treatment.
Radiation Dosimetry Estimates
Normal organ radiation doses for the first and second cycles in the same patients were not 
substantially different and were similar to those reported in the previous study.17 For 
example, a single cycle of treatment at the 12.0 mCi/m2 weekly for 3 weeks dose level 
resulted in cumulative radiation doses of 878 cGy (range, 417–1577 cGy) to the kidneys, 
1272 cGy (range, 758–1948 cGy) to the liver, 701 cGy (range, 524–997 cGy) to the lungs, 
and 233 cGy (range, 154–312 cGy) to the red bone marrow. Even with repeated cycles, the 
total cumulative dose still generally remained below the standard limits for the solid organs, 
but the combined cumulative dose to the red marrow was 510 cGy (range, 399–638 cGy). 
An example of antibody targeting is provided in Figure 2 along with radiation dose 
estimates calculated for the primary tumor (range, 39–44 grays).
Immunogenicity
Of the 32 treated patients who had adequate samples for HAHA assessment, only 1 patient 
developed an elevated titer of uncertain clinical significance (750 ng/mL 8 weeks after the 
initial treatment cycle, decreasing over time).
Treatment Responses
Of the 38 patients who received treatment, CT-based evaluations revealed PRs according to 
RECIST and stabilization for all dose levels (Table 3). One patient had SD after the first 
treatment cycle that converted to a PR after a second treatment cycle; otherwise, all of the 
best responses occurred after the first cycle. The overall disease control rate (CR + PR + SD, 
N = 22) was 58%, including 6 patients (16%) with PRs (all with stage IV disease) and 16 
patients (42%) with stabilization as their best response. All 5 patients with stage III disease 
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had SD, whereas 52% of patients with stage IV disease had disease control (PR, 6 of 17 
patients; SD, 11 of 17 patients). The median duration of disease control was 3.9 months 
(95% confidence interval [CI], 2.2–6.5 months) for all 22 patients, including 3.6 months 
(95% CI, 2.3–8.4 months) for the 6 patients with PRs.
Twenty-seven treated patients had elevated serum CA19-9 levels at baseline and had at least 
1 CA19-9 result after the first cycle before initiating additional cycles. The overall response 
rate was 33%, based on decreases >50% from baseline levels after the first cycle at all dose 
levels. Twenty-six percent of patients had a response based on a more stringent decrease of 
>75%.
Twenty-five treated patients had positive baseline FDG-PET studies with at least 1 PET 
study available after the first cycle before receiving additional treatment cycles. Standard 
uptake values (SUVs) were obtained for all index lesions. Responses were based on 
decreases of >25% from baseline for all index lesions or >50% for just the baseline lesion 
with maximal SUV value. PET-SUV decreases occurred at all dose levels, with overall 
response rates of 52% (all index lesions) and 36% (maximal baseline lesion only). Examples 
of PET responses to treatment are provided in Figure 2.
Survival
Of the 38 treated patients, 5 remained alive 15 to 25 months after starting treatment. Kaplan-
Meier estimated OS curves are provided in Figure 3. The 38 treated patients had a median 
OS of 7.7 months (95% CI, 5.6–9.6 months); and 58% (22 of 38 patients) survived for ≥6 
months; 26% (10 of 38 patients) survived for ≥1 year, and 46% (6 of 13 patients) of patients 
in the repeated cycle group were alive at >1 year. The median OS was 6.0 months (95% CI, 
5.2–8.0 months) for 33 patients with stage IV disease and 19.6 months (95% CI, 7.9–24.3 
months) for 5 patients with stage III disease. The 16 patients who were treated at the 2 
lowest dose levels (6.5 mCi/m2 and 9.0 mCi/m2 weekly for 3 weeks) had a median OS of 
6.3 months (95% CI, 3.0–12.1 months), and 2 patients remained alive at 15 months. The 22 
patients who were treated at the 2 highest dose levels (12.0 mCi/m2 and 15.0 mCi/m2 
weekly for 3 weeks) had a median OS of 8.0 months (95% CI, 5.6–9.8 months), and 3 
patients remained alive at 21 to 25 months. Assessing the impact of retreatment, 6 of those 
13 patients (46%) survived for ≥1 year and had a median OS of 11.8 months (95% CI, 8.0–
13.5 months) compared with 5.4 months (95% CI, 3.0–8.0 months) for the 25 patients who 
received only 1 treatment cycle (P < .034; log-rank test). Among the 13 patients who 
received ≥2 more cycles, 3 patients with stage III disease had a median OS of 24.3 months, 
whereas the remaining 10 patients had a median survival of 10.7 months.
DISCUSSION
Therapy with radiolabeled antibodies has achieved success in lymphomas, but objective 
responses rarely are reported in solid tumors with single-dose RAIT.23 Only limited efforts 
involving dose fractionation or administration with other systemic and potentially radiation-
enhancing drugs have been undertaken.24–26 To our knowledge, this is the first study 
describing the combination of a drug and RAIT as active in a solid tumor and particularly in 
a challenging disease like advanced PDC. In the first study of pretreated patients with PDC 
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who received a single dose of 90Y-hPAM4, several patients had transient responses by CT,17 
suggesting that the radiolabeled antibody was active by itself. This is encouraging, because 
objective responses rarely occur with standard doses of gemcitabine and erlotinib.2 The 
hypotheses for this study were: 1) RAIT fractionation would be more potent with less 
myelosuppression, 2) combination with a low gemcitabine dose of 200 mg/m2 weekly for 4 
weeks would further potentiate therapeutic benefit without substantially increasing toxicity, 
and 3) repeated cycles would be more effective than a single cycle. These hypotheses were 
confirmed. The imaging, pharmacokinetic, and radiation dosimetry data obtained at the first 
cycle in this study were similar to those reported with single-dose RAIT without 
gemcitabine in the previous study,17 and there were no changes in these parameters with 
repeated cycles. The 90Y-hPAM4 administrations were well tolerated with no infusion 
reactions. After completing this investigational treatment, 20 of 38 patients were able to 
receive various regimens of chemotherapy at different times during the course of their later 
therapy despite the dose-related myelosuppression induced with RAIT. Thus, combined 
RAIT plus chemotherapy may not limit subsequent chemotherapy.
With a median OS for all patients of 7.7 months, this regimen of a single treatment cycle 
provides evidence of modest antitumor activity for this combination therapy, especially 
because 5 patients with stage III disease contributed a median OS of 19.6 months. For those 
who received at least 2 treatment cycles, a median survival of 11.8 months was achieved; 
and, at 1 year, 46% remained alive (or 26% of all 38 patients who were treated at any dose). 
When considering only the 10 patients with stage IV disease, an median OS of 10.7 months 
was achieved. Repeated cycles will be required in future studies, but only approximately 
33% of patients in the current study received additional cycles at the option of the managing 
physician. Nevertheless, these initial results appear promising, even compared with recent 
reports from other trials, because FOLFIRINOX (fluorouracil, leucovorin, irinote-can, and 
oxaliplatin) required a median of 10 cycles to achieve a median survival of 11.1 months, and 
48.4% of patients remained alive at 1 year4: whereas the combination of gemcitabine plus 
nanoparticle albumin-bound paclitaxel (nab-paclitaxel) required a median of 6 cycles to 
achieve a median survival of 10.3 months, and similarly, 48% of patients remained alive at 1 
year.5 However, both of these therapy regimens had more severe adverse events, including 
neutropenia and febrile neutropenia4 and more fatigue and sensory neuropathy,5 than the 
reversible myelosuppression noted as the only major side effect in the current study. In this 
trial, most patients who received repeated cycles had a total of 8 very low doses of 
gemcitabine and 6 fractionated doses of RAIT; thus, the therapy was shorter in duration and 
less intensive than the other combination chemotherapy regimens. We appreciate that it is 
premature to compare our 1-arm, initial therapy trial with the other cited studies and that, as 
in most survival trials of investigational agents, further therapies administered also may 
contribute to improved patient outcome. Furthermore, the small number of patients who 
received repeated therapy cycles in this study could constitute a selection bias of patients 
with less aggressive disease.
Of the 38 treated patients, the overall disease control rate (CR + PR + SD) according to CT-
based RECIST criteria was 58%, including 6 patients (16%) with PRs (all with stage IV 
disease) and 16 patients (42%) with SD as their best response, and approximately 66% 
received only a single therapy cycle. Metabolic imaging (PET) and biomarkers (CA19-9) 
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confirmed efficacy; after the first cycle, 52% of patients (13 of 25) had negative or >25% 
reduced uptake in all lesions by FDG-PET SUV values, and 33% of patients (9 of 27) who 
had elevated CA19-9 levels at baseline had decreases >50% in serum levels. Comparing 
results after the first cycle between patients treated at the 2 highest dose levels (≥12.0 
mCi/m2 weekly for 3 weeks) and patients treated at the 2 lowest dose levels (≤9.0 mCi/m2 
weekly for 3 weeks), 18% versus 6%, respectively, had CT-confirmed PRs; 44% versus 
18%, respectively, had CA19-9 decreases; and 63% versus 33%, respectively, had PET-
confirmed improvements. Hence, these parameters responded in a dose-dependent, 
concordant manner and are consistent with the experience reported with nab-paclitaxel 
combined with gemcitabine.5
In the current study, patients received the same 90Y dose for each of their first or repeat 
cycles. And, as expected, the major toxicity was grade 3/4 neutropenia or thrombocytopenia, 
which increased with both dose level and retreatment. Although these findings generally are 
consistent with increasing radiation-absorbed doses to the red bone marrow, the current 
dosimetry methodology for predicting myelosuppression remains too limited to be applied 
on an individual basis other than to avoid exceeding generally accepted limits, which often 
are required for nonmyeloablative therapy studies. Here, this meant that the highest planned 
dose level of 15 mCi/m2 weekly for 3 weeks was not pursued further after several patients 
had their dose reduced to remain within these limits. Then, patients initially were entered 
into the second part of the study at the maximally tolerated 90Y dose level of 12 mCi/m2 
weekly for 3 weeks. This dose continued to be acceptable for the first cycle, because all 
cytopenias with follow-up were readily reversible with infrequently required hematologic 
support. However, the 12 mCi/m2 dose appeared to be too high for retreatment, because 
several patients developed prolonged and transfusion-dependent thrombocytopenia after a 
second cycle. Therefore, subsequent patients were enrolled at 9.0 mCi/m2. Although 1 
patient at 9.0 mCi/m2 developed thrombocytopenia that continued at grade 3 for at least 12 
weeks, all other occurrences of cytopenias with retreatment at dose levels ≤9 mCi/m2 were 
reversible.
Thus, based on the results from this phase 1 study, the maximum 90Y dose selected for 
further clinical development in this population is 12.0 mCi/m2 weekly for 3 weeks during 
the first cycle. However, because patients received the same dose for a second cycle in this 
study, the question of whether 9.0 mCi/m2 weekly for 3 weeks or a lower dose would be 
suitable for follow-up as a retreatment cycle after 12 mCi/m2 remains to be determined. 
Also, fractionated RAIT was administered only in combination with 4 weekly 
administrations of 200 mg/m2 gemcitabine. Thus, studies are ongoing to determine 
acceptable 90Y dosing for retreatment and whether higher gemcitabine doses are 
advantageous with RAIT.
In conclusion, this study confirmed the hypotheses that patients can tolerate higher 
cumulative radiation with fractionated dosing than with single doses and that low-dose 
gemcitabine can be combined effectively with repeated cycles of RAIT. Encouraging 
therapeutic activity and survival results were observed with this combination and will need 
to be confirmed in subsequent studies, including controlled trials. Finally, in a patient 
population often characterized by dismal outcome and poor quality of life, this novel 
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therapeutic approach was well tolerated, and it is noteworthy that it did not preclude patients 
from receiving subsequent chemotherapy during the course of their disease.
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This is the protocol schema. RAIT indicates fractionated radioimmunotherapy; 111In-
hPAM4, indium 111-labeled, humanized clivatuzumab tetraxetan; 90Y-hPAM4, yttrium 90-
labeled, humanized clivatuzumab tetraxetan; Gem, gemcitabine; PK, pharmacokinetics.
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These are examples of imaging from 3 patients. (a,b) These are anterior, planar indium 111-
labeled, humanized clivatuzumab tetraxetan (111In-hPAM4) images from 1 patient who 
received 2 treatment cycles, both at 12.0 mCi/m2 weekly for 3 weeks. Uptake was observed 
at the site of the known primary pancreatic mass (arrows). (a) The pancreatic mass, initially 
measured as 3.7 × 2.6 cm, received 39 grays (Gy) in the first cycle. (b) After decreasing to 
1.8 × 2.9 cm, the pancreatic mass received 44 Gy in the second cycle. The patient’s disease 
remained stable until 8 weeks after the second treatment cycle, when disease progression 
occurred with the finding of new omental lesions. (c) Positron emission tomography–18F-
deoxyglucose (PET-FDG) imaging before treatment shows normal heart (H) activity and 
reveals uptake in the primary pancreatic tail mass (white arrow) and in 3 left-lobe liver 
metastases (red arrows). (d) The uptake is no longer apparent 4 weeks after treatment. 
Serum CA19-9 titers decreased from 1297 at study entry to 77 at 4 weeks after treatment. (e) 
In another patient, PET-FDG imaging before treatment reveals uptake in primary pancreatic 
mass (yellow arrow), in portacaval lymph nodes (white arrow), and in a large hepatic mass 
extending from the dome of the liver (red arrow). (f) The uptake is no longer observed 4 
weeks after treatment.
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These are Kaplan-Meier estimates of overall survival for all 38 treated patients. (a) Results 
at the 2 highest dose levels (12.0 mCi/m2 and 15.0 mCi/m2 weekly for 3 weeks) are 
compared with results at the 2 lowest dose levels (6.5 mC1/m2 and 9.0 mCi/m2 weekly for 3 
weeks). (B) Results for all patients and for patients who were retreated are compared with 
results for patients who received only a single cycle of treatment.
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Table 1















 III (locally advanced) 6
 IV (metastatic) 36
Time from diagnosis
 Median (range), mo 0.7 (0.1–3.3)
Prior therapy: No. of patients
 Chemotherapya 0
 External radiation 0
 Surgeryb 7
 Stent placementsc 6
CT-identified tumorsd
 Lesion location: No. of patients
  Pancrease 40
  Liverf 23
  Extrahepatic abdomeng 20
  Chest/lung 3
 Largest lesion: Median (range), cm
  Pancreas 4.6 (2.1–9.0)
  Liver 2.4 (1.6–4.3)
  Extrahepatic abdomen 1.8 (1.1–5.0)
  Chest/lung 2.5 (1.1–3.4)
Hematology: Median (range)
 Hemoglobin, g/dLh 13.2 (9.9–15.7)
 Neutrophils, K/μL 5.0 (2.7–12.7)
 Platelets, K/μL 244 (123–595)
CA19-9: Median (range), U/mL 1534 (<1–257,560)
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Variable Value
 No. with elevated CA19-9 35
 No. with CA19-9 >1000 U/mL 23
Abbreviations: CT, computed tomography; ECOG, Eastern Cooperative Oncology Group.
a
This was chemotherapy for advanced disease (1 patient had received gemcitabine, but as adjuvant therapy, 41 months earlier after undergoing 
pancreaticoduodenectomy).
b
Surgery was palliative gastrojejunostomy with or without biliary bypass (N = 5) or pancreaticoduodenectomy but recurrence with advanced 
disease at study entry (N = 2).
c
These included biliary stents (N = 5) and a gastrointestinal stent (N = 1).
d
These were measurable tumor masses on baseline CT evaluation.
e
A pancreatic mass was not present in 2 patients who underwent previous pancreaticoduodenectomy.
f
These patients had 1 (N = 6), 2 (N = 7), 3 (N = 7), or more (N = 3) liver metastases.
g
These patients had 1 (N = 10), 2 (N = 6), or more (N = 4) abdominopelvic lymph nodes, soft-tissue nodules, or implants.
h
Two patients were granted waivers for hemoglobin levels <11 g/dL.
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Table 3
Post-Treatment Responses
No. of Patients (%)
CT: Best Responsea Total No. Disease Control: CR+PR+SD PR+/SD
Overall 38 22 (58) 6 (16)/16 (42)
Dose level
 1 4 3 (75) 1 (25)/2 (50)
 2 12 5 (42) 1 (8)/4 (33)
 3 17 12 (71) 3 (18)/9 (53)
 4 5 2 (40) 1 (20)/1 (20)
No. of Patients (%)
CA19-9: Best Response to First Treatment Cycleb Total No. >50% Decrease >75% Decrease
Overall 27 9 (33) 7 (26)
Dose level
 1 2 1 (50) 1 (50)
 2 9 1 (11) 1 (11)
 3 12 4 (33) 2 (17)
 4 4 3 (75) 3 (75)
No. of Patients (%)
FDG-PET: Best Response to First Treatment 
Cyclec
Total No. All Index Lesions >25% Decreased >50% Maximum Lesion Decreasee
Overall 25 13 (52) 9 (36)
Dose level
 1 2 2 (100) 2 (100)
 2 7 1 (14) 0 (0)
 3 11 7 (64) 4 (36)
 4 5 3 (60) 3 (60)
Abbreviations: CR, complete response; CT, computed tomography; FDG-PET, positron emission tomography–18F-deoxyglucose; PR, partial 
response; SD, stable disease.
a
The best response achieved is listed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. No patient achieved a CR. 
All PRs occurred in patients with stage IV disease.
b
These were 27 patients who had elevated baseline CA19-9 serum levels and achieved CA19-9 serum levels greater than or equal to baseline levels 
before receiving any retreatment.
c
These were 25 patients who had positive baseline PET studies and had the same or improved post-treatment PET studies before receiving any 
retreatment.
d
Each index lesion standardized uptake value decreased >25% from baseline.
e
The lesion with highest pretreatment standardized uptake value (19 pancreatic primaries, 6 hepatic metastases) decreased >50% from baseline.
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